Clinical Trials Logo

Mild Alzheimer's Disease clinical trials

View clinical trials related to Mild Alzheimer's Disease.

Filter by:

NCT ID: NCT01061489 Completed - Clinical trials for Mild Cognitive Impairment (MCI)

Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment

Start date: August 2009
Phase: N/A
Study type: Interventional

Age-related cognitive decline is unavoidable. However, recent results of neuroplasticity-based research show that neuroplasticity-based training and physical activity might have the potential to decelerate or even reverse effects of aging and age-related cognitive impairments. Little is known whether these results also apply to pathological processes of aging such as mild cognitive impairment (MCI) and dementia. This multi-center study aims at investigating efficiency and feasibility of a neuroplasticity-based auditory discrimination training and a physical fitness training for patients suffering from mild cognitive impairment or mild Alzheimer's disease (Mini Mental State Examination, MMSE > 19). Evaluation will include neuropsychological testing, electroencephalography (EEG) and magnetic resonance imaging (MRI) measurements as well as blood and liquor analyses.

NCT ID: NCT01013610 Completed - Clinical trials for Mild Alzheimer's Disease

An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

Start date: November 2009
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, multiple dose plasma pharmacokinetics (PK) of LNK-754 in male and female elderly volunteers after dosing with LNK-754 for 7 days and in subjects with mild Alzheimer's Disease after dosing with LNK-754 for 28 days.

NCT ID: NCT00706186 Terminated - Clinical trials for Mild Alzheimer's Disease

Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients

ALD
Start date: n/a
Phase: Phase 4
Study type: Interventional

Eligible patients will undergo this open label initial safety and feasibility study investigating the use of 6 g/day sodium oxybate in mild AD. A total of 5 visits are included with this trial and total subject participation duration of 7-8 weeks. The screening phase will include an initial screening visit and a screening PSG night. After successful screening, subjects will complete a baseline PSG night and undergo a third PSG night to monitor initial safety and compliance with study drug at a dosage of 4.5 g/day of sodium oxybate. Thus the subject will undergo three consecutive nights of PSG in the sleep center. The patient will maintain a dosage of 4.5 g/day for a duration of 7 days leading to Treatment Visit 1. After successful assessment at Treatment Visit 1, the dosage will be increased to 6 g/day for the duration of the trial. At Treatment Visit 2 (day 21), the dosage will be increased to a dosage of 9 g/day, if tolerated by the patient. The remaining visit will occur at 6 weeks after baseline, with Treatment Visit 3 consisting of two consecutive nights of PSG. Participation will be complete after this visit. Phone follow-up will be made at one week post completion visits to assess any wash-out symptoms. Please refer to Figure for flow of the study design.

NCT ID: NCT00582855 Terminated - Clinical trials for Amnestic Mild Cognitive Impairment

Effect of AQW051 in Patients With Memory Impairment

Start date: December 2007
Phase: Phase 2
Study type: Interventional

This study will investigate AQW051 in patients with either mild Alzheimer's disease or amnestic mild cognitive impairment. The effect on cognitive impairment will be measure using validated computerized tests which measure cognitive function. This study will also explore the safety and tolerability of AQW051 in these patients.

NCT ID: NCT00243451 Completed - Clinical trials for Mild Cognitive Impairment

Early Detection of Mild Cognitive Impairment in Individual Patients

Start date: September 2003
Phase: N/A
Study type: Observational

Our central hypothesis is that the early metabolic lesions of MCI can be reliably detected in individual subjects by objective analysis of [18]F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) brain images, earlier and more accurately than by subjective clinician rating.